Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression
Authors:
- U N LassenULU N Lassen
- K ØsterlindKØK Østerlind
- F R HirschFHF R Hirsch
- B BergmanBBB Bergman
- P DombernowskyPDP Dombernowsky
- H H HansenHHH H Hansen
Open Access
- 14 January 1999
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 79 (3-4) , 515-519
Abstract
Based on an increased frequency of early death (death within the first treatment cycle) in our two latest randomized trials of combination chemotherapy in small-cell lung cancer (SCLC), we wanted to identify patients at risk of early non-toxic death (ENTD) and early toxic death (ETD). Data were stored in a database and logistic regression analyses were performed to identify predictive factors for early death. During the first cycle, 118 out of 937 patients (12.6%) died. In 38 patients (4%), the cause of death was sepsis. Significant risk factors were age, performance status (PS), lactate dehydrogenase (LDH) and treatment with epipodophyllotoxins and platinum in the first cycle (EP). Risk factors for ENTD were age, PS and LDH. Extensive stage had a hazard ratio of 1.9 (P = 0.07). Risk factors for ETD were EP, PS and LDH, whereas age and stage were not. For EP, the hazard ratio was as high as 6.7 (P = 0.0001). We introduced a simple prognostic algorithm including performance status, LDH and age. Using a prognostic algorithm to exclude poor-risk patients from trials, we could minimize early death, improve long-term survival and increase the survival differences between different regimens. We suggest that other groups evaluate our algorithm and exclude poor prognosis patients from trials of dose intensification.Keywords
This publication has 22 references indexed in Scilit:
- Outcome of combination chemotherapy in extensive stage small-cell lung cancer: Any treatment related progress?Lung Cancer, 1998
- 88 Oral etoposide (VP-16) every 3 wks. or continuously to elderly patients with small cell lung cancer (SCLC): Preliminary results of a randomized studyLung Cancer, 1997
- Five-Day Oral Etoposide2 Treatment for Advanced Small-Cell Lung Cancer: Randomized Comparison With Intravenous ChemotherapyJNCI: Journal of the National Cancer Institute, 1997
- Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow upAnnals of Oncology, 1996
- Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma: A study of the lung cancer study group of west JapanCancer, 1996
- Treatment-related deaths in small cell lung cancer trials: can patients at risk be identified?Lung Cancer, 1994
- Predicting septic complications of chemotherapy: An analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsisEuropean Journal of Cancer, 1993
- Management of Small Cell Lung Cancer: A Summary of the Third International Association for the Study of Lung Cancer Workshop on Small Cell Lung CancerJNCI: Journal of the National Cancer Institute, 1990
- Drug monitoring of etoposide (VP16-213)Cancer Chemotherapy and Pharmacology, 1987
- Autologous bone marrow transplantation following high-dose chemotherapy with cyclophosphamide, BCNU and VP-16 in small cell carcinoma of the lung and a review of current literatureEuropean Journal of Cancer and Clinical Oncology, 1984